je.st
news
Tag: merck
Merck Announces Second-Quarter 2015 Financial Results
2015-07-28 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Second-Quarter 2015 Non-GAAP EPS of $0.86, Excluding Certain Items; GAAP EPS of $0.24 Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.52 to $1.71 Second-Quarter 2015 Worldwide Sales Were $9.8 Billion, a Decrease of 11 Percent, Including a 7 Percent Net Unfavorable Impact from Acquisitions and Divestitures and a 7 Percent Negative Impact from Foreign Exchange Second-Quarter Results Reflect Sales Growth in Hospital Acute Care, Oncology and Diabetes and Sales Declines in Cardiovascular and Hepatitis C European Commission Approved KEYTRUDA for the Treatment of Advanced Melanoma; FDA Accepted sBLA for KEYTRUDA in Advanced Non-Small Cell Lung Cancer Grazoprevir/Elbasvir Chronic Hepatitis C Combination Regimen Accepted for Regulatory Review in Both the United States and European Union KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2015. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
2015-07-28 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & MISGAV, Israel KENILWORTH, N.J. & MISGAV, Israel--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and cCAM Biotherapeutics announced today that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orcCAM Investor/Media Relations:Tsipi Haitovsky, +972-525-989892 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: portfolio
acquisition
enhances
merck
Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection
2015-07-28 12:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Granted FDA Priority Review with Target Action Date of January 28, 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Sarra Herzog, (201) 669-6570orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: and
food
application
administration
Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA (Ceftolozane and Tazobactam)
2015-07-27 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic ZERBAXA (ceftolozane and tazobactam) for the treatment of the following infections in adults: complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: positive
opinion
receives
antibiotic
Merck, Baupost join $55M investment in early-stage biotech, RaNA
2015-07-24 18:09:58| Biotech - Topix.net
After selling his company Idenix Pharmaceuticals to Merck & Co. for $3.9 billion last August, Ronald Renaud has received support again from the New Jersey drug giant, this time in financing for his new company.
Tags: join
investment
biotech
merck
Sites : [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] next »